Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02626871

Acronym

CAREAVR

Enrollment

850

Registered

2015-12-10

Start date

2002-01-31

Completion date

2015-12-31

Last updated

2017-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Stenosis, Atrial Fibrillation, Bleeding, Stroke, Transient Ischemic Attack

Brief summary

The primary purpose of the FIN-bioAVR registry is to assess the incidence of AF, strokes and major bleeding events in patients undergoing aortic valve replacement. This retrospective multicenter registry will include 850 patients with aortic valve replacement using bioprosthesis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* patients undergoing aortic valve bioprosthesis implantation

Exclusion criteria

* mechanical heart valves in any position

Design outcomes

Primary

Measure	Time frame
Stroke	10 years
Mortality	10 years
atrial fibrillation	10 years
major bleeding	10 years

Countries

Finland

Outcome results